Is AMCR a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on Berry Global synergies, with revenue (fy2026, to june) at ~$23.5B. The bear case rests on leverage is the central risk. Analysts covering it are spread from $42.00 to $60.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Leverage is the central risk. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $42.00, -9.1% from the $46.23 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

Berry Global synergies. The single biggest lever is cost and revenue synergy from the Berry merger. The most optimistic analyst target on AMCR is $60.00, +29.8% from the $46.23 price. That figure is only reachable if this thesis works close to its best case.

Leverage is the central risk. With ~$12.9 billion of net debt and leverage near ~3.5x, a stumble in earnings or cash flow would slow deleveraging and could pressure the dividend, which already absorbs roughly half of the ~$2.5 billion free cash flow management is guiding to. Higher interest and tax expense is already a ~$0.10 to ~$0.12 per share headwind in the transition period. Resin and input costs are a second exposure: Middle East disruption in 2026 drove what management called unprecedented inflation, and while Amcor passed through ~$280 million of price in the June quarter, pass-through lags can squeeze margins and tie up working capital, as the ~$500 million build showed. Volumes have been weak for years, especially in healthcare (lower-margin categories), North American beverage, and liquids, and the recent turn is only one quarter old. Integration execution matters too, since the 2027 EPS growth call leans heavily on synergies. Regulatory pressure on single-use plastics, including EU packaging rules and extended producer responsibility fees, could raise costs or shift demand toward paper and reusable formats. Finally, law firms have advertised investigations on behalf of former Berry holders, though no securities class action had been filed as of October 2026. The most pessimistic published target is $42.00, -9.1% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

Global consumer and healthcare packaging maker, now combined with Berry Global, supplying the films, pouches, bottles and closures behind everyday food, drink and medical products.

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Berry Global synergies) stalling in the reported numbers rather than in the narrative, the risk above (leverage is the central risk) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

Amcor designs and manufactures consumer packaging. Its Global Flexible Packaging Solutions segment (~$12.8 billion of fiscal 2026 sales) makes films, pouches, lidding, shrink bags and sterile medical packaging used by food, pet care, coffee, healthcare and personal care brands. Its Global Rigid Packaging Solutions segment (~$10.7 billion) makes PET bottles, plastic containers, closures, cups and tubs, much of it from the former Berry Global. Customers include large consumer goods and drinks companies, and contracts often include clauses that pass resin cost changes through to customers with a lag. Amcor operates hundreds of plants across more than 40 countries, employs about 75,000 people, and is headquartered in Zurich, with its primary listing on the NYSE under AMCR and CDIs trading on the ASX under AMC.

It did not. Amcor completed a one-for-five reverse stock split on January 14, 2026, and shares began trading on a split-adjusted basis on January 15. That cut the share count from roughly 2.3 billion to about 461 million and multiplied the price by five, so a ~$9.30 pre-split price became ~$46.50. Nothing about the company's value changed. Per-share figures in Amcor's filings, including EPS and the dividend, have been restated for the split, which is why fiscal 2026 adjusted EPS reads ~$4.02 rather than ~$0.80. Anyone comparing current quotes with 2025 charts or older articles needs to divide today's price by five (or multiply the old one by five) to make a fair comparison.

Amcor's most recent release, on August 12, 2026, covered the June quarter and fiscal year 2026. Full-year net sales were ~$23.5 billion (up ~57%, mostly from Berry), adjusted EBIT ~$2.8 billion, and adjusted EPS ~$4.02, up ~13%. The June quarter was stronger: sales of ~$6.4 billion, adjusted EPS of ~$1.23 (up ~23%), and volumes slightly positive for the first time in a while. Synergies of ~$285 million beat the year-one target. Free cash flow of ~$1.3 billion missed the outlook by about $200 million because of resin-driven working capital. No new results were released in the week of October 26, 2026; the next report covers the transition period.